Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 10, 2020 (Earliest event reported)
Reporting Period: Events occurring on February 10 and February 11, 2020.
Key Financial Metrics and Capital Structure
- Debt Conversion: On February 10, 2020, the Company issued 86,284,252 shares of common stock upon the exercise of conversion rights by holders of indebtedness totaling $86,284 (inclusive of accrued and unpaid interest).
- Outstanding Convertible Debt: As of February 11, 2020, the outstanding principal amount of convertible debt is $7,398,899.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
- Liquidity: The filing text does not provide a clear value for current liquidity positions or cash balances.
Material Changes and Legal Developments
- Unregistered Sale of Equity: The Company issued over 86 million shares to satisfy debt conversion obligations, relying on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933.
- Court Order (Temporary Restraining Order): On February 11, 2020, the U.S. District Court for the Eastern District of New York issued a temporary restraining order in the matter of Coventry Enterprises, LLC vs. BioRestorative Therapies, Inc.
- Restrictions on Issuance: The Court enjoined the Company from issuing any additional shares of stock, except to fulfill the plaintiff's share reserve or conversion requests, until those requests are fulfilled. The Company is also enjoined from reserving authorized shares for any other party.
- Upcoming Hearing: A hearing regarding the plaintiff's application for a preliminary injunction is scheduled for February 13, 2020.
Guidance, Risks, and Contingencies
- Event of Default Risk: The inability to issue shares due to the Court's restraining order may constitute an event of default under the provisions of the outstanding convertible notes.
- Acceleration of Debt: An event of default may result in the acceleration of amounts payable pursuant to the notes, potentially requiring immediate repayment of the $7,398,899 outstanding principal.
- Management Commentary: The filing does not contain forward-looking guidance or management commentary regarding future operations beyond the immediate legal constraints.
Investor Verification Checklist
- Verify the status of the hearing scheduled for February 13, 2020, regarding the preliminary injunction.
- Confirm whether the inability to issue shares has triggered a formal event of default under the convertible note agreements.
- Assess the Company's ability to satisfy the plaintiff's share reserve requests without violating the Court's order.
- Review the impact of the 86 million share issuance on existing shareholder dilution.
- Monitor for any subsequent filings regarding the acceleration of the $7.4 million convertible debt.